SERIF
Live / Applied — Statement of use — processing complete, to examiner (as of 28 Jul 2026)
What this means for you
Not registered yet, but its 09 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98978689
- Mark type
- Word mark
- Filed
- 09 Jul 2024
- Published for opposition
- 25 Feb 2025
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 001 — Chemicals: Biological and chemical agents for scientific and research use, namely, nucleic acids for use in the manufacture of pharmaceuticals, reagents for pharmaceutical research purposes, and cells for scientific and research use
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases
Owner
- SERIF BIOMEDICINES, INC., CAMBRIDGE, MA, US
- SERIF BIOMEDICINES, INC., CAMBRIDGE, MA, US
- Flagship Labs 87, Inc., Cambridge, MA, US
Prosecution history
- 29 Jul 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Jul 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 17 Apr 2026 — USE AMENDMENT FILED
- 28 Jul 2026 — SOU EXTENSION 2 GRANTED
- 16 Apr 2026 — SOU EXTENSION 2 FILED
- 23 Jul 2026 — DIVISIONAL PROCESSING COMPLETE
- 17 Apr 2026 — DIVISIONAL REQUEST RECEIVED
- 17 Apr 2026 — TEAS REQUEST TO DIVIDE RECEIVED
- 08 Jul 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 17 Apr 2026 — TEAS STATEMENT OF USE RECEIVED
- 17 Apr 2026 — SOU TEAS EXTENSION RECEIVED
- 18 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Oct 2025 — SOU EXTENSION 1 GRANTED
- 17 Oct 2025 — SOU EXTENSION 1 FILED
- 17 Oct 2025 — SOU TEAS EXTENSION RECEIVED